Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Health Care Privacy Shield Law topic
No spam. Unsubscribe anytime.
Attorney general, health departments and advocates urge tighter ‘shield law’ protections for reproductive and gender-affirming care
Summary
The Joint Judiciary hearing drew health officials, the attorney general’s office and providers to press for changes to Massachusetts’ 2022 shield law — including stronger privacy for electronic medical records, expanded protection against out-of-state subpoenas and a state-level EMTALA guarantee for hospitals.
State and health officials, clinicians and advocacy groups told the Joint Committee on the Judiciary they support expanding Massachusetts’ 2022 “shield law” to protect patients and providers of abortion and gender-affirming care from out-of-state civil or criminal actions.
Attorney General Andrea Campbell’s office described specific additions: extending the bar on cooperation with out-of-state investigations to all state or local agencies, granting the attorney general explicit authority to enforce the shield law, and protecting data associated with the provision of protected health care — including electronic medical records. Department of Public Health witnesses asked for similar protections, warning that federal enforcement ambiguity since CMS guidance changes could leave hospitals uncertain about emergency treatment obligations.
Witnesses and agency representatives highlighted several concrete changes discussed in the bill: exemption of reproductive or gender-affirming medications from the Prescription Monitoring Program (PMP) disclosures; permitting practice-level (rather than clinician-level) labeling; and a state-level EMTALA-like duty requiring hospitals to provide stabilizing emergency care (including when the stabilizing care is an abortion for obstetric emergencies). Clinicians said practice-name labeling prevents out-of-state harassment of individual prescribers while permitting follow-up care; the bill includes a carve out to comply with federal law where required (for example for scheduled controlled substances).
Several healthcare advocates and the Department of Public Health said the national landscape has become more hostile since 2022: they described federal guidance rollbacks and active litigation in other states against providers. The attorney general’s office and DPH emphasized that the proposed updates would strengthen patient privacy and provider protection, help ensure hospitals comply with emergency care duties, and would protect parents of transgender youth from out-of-state determinations used to punish families.
Committee members asked technical questions about interaction with federal law (EMTALA and PMP rules), pharmacy labeling and whether practice-level labeling could complicate board or licensing investigations; legal and agency witnesses said they had reviewed these questions with the Attorney General and DPH and proposed carve-outs for federally controlled substances and coordination with licensing boards.
No committee votes were taken; staff and sponsors said they would continue drafting technical fixes based on committee questions.
